Skip to main content

Market Overview

Vetr Crowd No Longer Uber-Bearish On Puma Biotech

  • Shares of Puma Biotechnology Inc (NYSE: PBYI) plunged nearly 20 percent on Friday.
  • The Vetr crowd upgraded its rating on Puma Biotech to two stars out of a possible five from a prior one-star rating.
  • The Vetr crowd's less-bearish rating is accompanied by its crowd-sourced price target of $65.10, implying further downside is likely.

Shares of Puma Biotechnology, a bio-pharmaceutical company that develops treatment for cancer hit a new 52-week low of $56.46.

Investors and traders were likely reacting to the company's three-year DFS follow up results from its ExteNET trial with neratinib. The company noted that the trial with neratinib resulted in a 33 percent reduction of risk of invasive disease recurrence or death versus placebo.

As shares of Puma sank on Friday, the Vetr crowd turned slightly less bearish on the company by upgrading its rating to two stars out of a possible five from a prior rating of just one star. Sixty-two percent of the crowd's ratings are bullish, however, the crowd-sourced price target of $65.10 implies a further downside of nearly 6 percent.

Related Link: Tesla Gets Upgraded By Vetr Crowd, Now 3.5-Star Rated

The Vetr crowd's bearish stance towards biopharmaceutical companies that focuses on cancer-related drugs does not extend to some of Puma's peers. For example, Clovis Oncology Inc (NASDAQ: CLVS), a biopharmaceutical company that develops and commercializes anti-cancer agents, is highly regarded by the crowd.

The Vetr crowd rates Clovis' stock a five star out of five rating with a crowd-sourced price target of $40.55, implying an upside just shy of 30 percent. However, it should be noted that only 60 percent of the crowd's ratings are bullish.

Latest Ratings for CLVS

Nov 2020SVB LeerinkMaintainsUnderperform
Nov 2020HC Wainwright & Co.MaintainsBuy
May 2020HC Wainwright & Co.ReiteratesBuy

View More Analyst Ratings for CLVS
View the Latest Analyst Ratings


Related Articles (CLVS + PBYI)

View Comments and Join the Discussion!

Posted-In: biotechnology Cancer Drugs neratinib VetrBiotech Crowdsourcing Analyst Ratings General

Latest Ratings

GDWolfe ResearchDowngrades
QRTEAB of A SecuritiesInitiates Coverage On
ABB of A SecuritiesDowngrades42.0
VCTRB of A SecuritiesUpgrades32.0
BSIGB of A SecuritiesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at